You are here

  • Home
  • Archive
  • Volume 14, Issue 9
  • Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor

Article metrics

Article menu

Download PDFPDF

XML
Case report
Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor

 

Online download statistics by month:

Online download statistics by month: September 2021 to April 2024

AbstractFullPdf
Sep 202132632679
Oct 202136936450
Nov 202119218926
Dec 202112011727
Jan 2022525116
Feb 2022767221
Mar 2022747224
Apr 202212412330
May 2022878522
Jun 2022838222
Jul 2022646418
Aug 202210710613
Sep 2022929115
Oct 2022717127
Nov 2022888817
Dec 202244445
Jan 2023586014
Feb 202310810015
Mar 2023727113
Apr 2023676517
May 2023645826
Jun 2023656514
Jul 2023494321
Aug 2023747341
Sep 2023282516
Oct 202333317
Nov 2023393711
Dec 2023373511
Jan 202421217
Feb 2024161410
Mar 2024474448
Apr 2024303111
Total27772718694